SOURCE: Paragon Financial Limited
NEW YORK, NY--(Marketwire - Jul 27, 2012) - The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 35 percent and 33 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Novavax, Inc. (NASDAQ: NVAX) and Cytori Therapeutics Inc. (NASDAQ: CYTX).
Access to the full company reports can be found at:
Despite having to negotiate a more challenging regulation process, biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."
Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.
Novavax is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Shares of the company soared over 20 percent on Wednesday after the company released positive results from a Phase IIb clinical trial.
Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Their scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. Shares of the company are up 12 percent year-to-date.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: